drugset / Trial / NCT00839501
Effect of Potassium and Acetazolamide on People With Andersen-Tawil Syndrome
Phase 1
Terminated
3 enrolled
University of Rochester
National Institute of Neurological Disorders and Stroke (NINDS) · collabOffice of Rare Diseases (ORD) · collabRare Diseases Clinical Research Network · collab
NaSingle-groupDouble-blindTreatment
Summary
Andersen-Tawil Syndrome (ATS) is a rare genetic disorder that causes episodes of muscle weakness, potentially life-threatening changes in heart rhythm, and skeletal developmental abnormalities. The cause of some ATS cases remains unknown, and no specific treatments have been established. The purpose of this study is to determine whether potassium supplements and/or the medication acetazolamide affect the duration of muscle weakness and heart rhythm abnormalities in people with ATS.
Timeline
- Start
- 2008-12
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetazolamide | Small molecule | 250 mg | Oral |